Peptide Reference
Lixisenatide
Lixisenatide
A once-daily GLP-1 receptor agonist (Adlyxin) with a shorter duration of action, providing post-meal glucose control.
Status
approved
Category
weight loss
Typical cost
$500-800/month
Mechanism
Short-acting GLP-1 agonist primarily targeting postprandial glucose. Stimulates insulin secretion after meals. Less effect on fasting glucose compared to longer-acting GLP-1s.
Potential benefits
- Post-meal glucose control
- Daily dosing
- Moderate weight loss
- Established safety
Reported side effects
- Nausea
- Vomiting
- Injection site reactions
- Daily injection burden
Common dosing references
subcutaneous
10-20mcg · Daily
Ongoing
Research notes
GetGoal trials - Lixisenatide efficacy
2013
Demonstrated postprandial glucose improvements in type 2 diabetes
Regulatory and sourcing notes
FDA-approved (Adlyxin) for type 2 diabetes. Less commonly prescribed than other GLP-1s.
Prescription required. Less commonly used than semaglutide or liraglutide. Good for post-meal glucose spikes.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.
Related peptides